March 13, 2013

Received his HBSc and MA in Experimental Psychology from Lakehead University (Thunder Bay, ON), his PhD in Neuroscience from Rush University Medical Center (Chicago, IL) and completed a post-doctoral fellowship at Harvard Medical School (Boston, MA) where he also joined their faculty. Dr. Koprich’s research interests include animal models of Parkinson’s disease and the preclinical evaluation of novel disease modification and symptomatic therapeutics. In recent years, his work has led to the development of progressive rodent and non-human primate models of PD alpha-synucleinopathy. These and other studies are detailed in over 40 peer reviewed publications.

In addition to his role at Atuka, Dr. Koprich is visiting Professor of Neurology at Huashan Hospital/ Fudan University and occasionally serves as a lecturer at the University of Toronto.

Publications

Description & References:

Product Spec:

CAS No.:

Molecular Structure:


Joined Atuka in 2003. He received his B.Sc. in pharmacology from the University of Manchester in 1999 and Ph.D. in Neuropharmacology from King’s College London in 2003. In addition to his role in Atuka, Dr Johnston has an academic position focused primarily on the pharmacology of Parkinson’s disease at University Health Network (2003-present). Dr Johnston has considerable experience in pre-clinical PD models and the development and translation of novel therapies that are featured in 51 peer-reviewed publications.

Publications

Description & References:

Product Spec:

CAS No.:

Molecular Structure:


Joined Atuka in 2011. He has a Ph.D. in Neuroscience, from the University of Manchester, UK (1997) and has more than 15 years’ experience in Parkinson’s disease research. Previously, he held the position of Chief Operating Officer at a CRO where he lead translational research that has supported the assessment of efficacy of more than 30 drug candidates in rodent and non-human primate models of PD, 7 of which advanced to clinical studies. These and other studies are detailed in 31 peer-reviewed publications.

Publications

Description & References:

Product Spec:

CAS No.:

Molecular Structure:


Jonathan founded Atuka in 2003 and was its first CEO. He has a Ph.D. in Neuroscience, from the University of Manchester, UK (1991) and has more than 25 years’ experience in Parkinson’s disease research managing teams that have identified and validated many drug targets for PD. He has lead translational research that has supported the assessment of efficacy of more than 70 drug candidates in non-human primate models of PD and the advancement of 16 drug candidates to clinical studies. These and other studies are detailed in over 200 peer-reviewed publications.

In addition to his role in Atuka, Dr Brotchie enjoys a reputation for excellence as an academic researcher, leading research programs at University Health Network (2002-present) and University of Manchester (UK, 1991-2002).

Publications

Description & References:

Product Spec:

CAS No.:

Molecular Structure: